Denmark· DK-28106031317
Kymriah
A tisagenlecleucel product containing tisagenlecleucel, registered in Denmark by Novartis Europharm Limited. The same ATC class is registered in 11 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Tisagenlecleucel is registered in 11 of 19 countries.
Countries holding a registration under ATC L01XL04 (tisagenlecleucel), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 7 of them publish a price we can compare per daily dose
Tisagenlecleucel · ATC L01XL04
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Tisagenlecleucel
- Manufacturer
- Novartis Europharm Limited
- Country
- Denmark (DK)
- ATC code
- L01XL04
- ATC class
- Tisagenlecleucel
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106031317
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
60 interactions on record for tisagenlecleucel.
Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tisagenlecleucel · interactions on record
60 records
- 28 severe
- 32 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01XL04
Tisagenlecleucel, as other registers publish it.
- NorwayKymriahNovartis Europharm Limited
- IcelandKymriahNovartis Europharm Limited*
- PolandKymriahNovartis Europharm Limited
- FinlandKymriahNovartis Europharm Limited
- CzechiaKYMRIAHNovartis Europharm Limited, Dublin
- CanadaKYMRIAHNOVARTIS PHARMACEUTICALS CANADA INC
- BelgiumKymriah 1,2 x 10*6 – 6 x 10*8 cellsNovartis Europharm
- NetherlandsKymriah, dispersie voor infusieNovartis Europharm Limited
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d181ce52-984e-4cd1-834c-09fd341aad27 GET /v1/drugs/d181ce52-984e-4cd1-834c-09fd341aad27?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "infusionsvæske, dispersion",
"source": "dkma",
"strength": "CAR-positive Tceller",
"auth_role": "MOD",
"dk_drugid": "28106031317",
"substance": "Tisagenlecleucel",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "43335"
}See everything about tisagenlecleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.